Skip to content
Screener

LB Pharmaceuticals Inc LBRX Q1 2026 earnings

Reported May 12, 2026 · Before market open

EPS-$0.67Beat by $0.08
EPS estimate-$0.75

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$1.61

Financials

Q1 2026

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M—
Total debt$3.5M—
Total equity$378.7M+481%
Total assets$393.5M—

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$707.12M—
Enterprise value$389.92M—

Returns & leverage

See full
Debt / equity0×—
Current ratio35.7×—

Versus estimates

Diluted EPS

Q2 2026-$1.71Miss by $0.91
Q1 2026-$0.67Beat by $0.08
Q4 2025-$0.45In lineQ3 2025-$0.61Miss by $0.04

FAQ

When did LB Pharmaceuticals Inc report Q1 2026 earnings?
LB Pharmaceuticals Inc (LBRX) reported Q1 2026 earnings on May 12, 2026 before market open.
What were LB Pharmaceuticals Inc's Q1 2026 revenue and EPS?
LB Pharmaceuticals Inc reported eps of $-0.67 for Q1 2026.
Did LB Pharmaceuticals Inc beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.75 by $0.08.
Where can I find LB Pharmaceuticals Inc's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-219529) and the 10-Q periodic report (0001193125-26-219607) directly on SEC EDGAR. The filing index links above go to sec.gov.